MediWound FY2026 Earnings Forecast Raised by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of MediWound in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings of ($1.86) per share for the year, up from their previous estimate of ($2.02). The consensus estimate for MediWound’s current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for MediWound’s Q4 2026 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.45) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($1.18) EPS and FY2029 earnings at $0.51 EPS.

Other equities analysts have also issued research reports about the stock. TD Cowen reissued a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Finally, Oppenheimer restated an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.00.

Check Out Our Latest Research Report on MDWD

MediWound Trading Up 5.0%

Shares of NASDAQ MDWD opened at $13.55 on Tuesday. MediWound has a 12 month low of $11.80 and a 12 month high of $19.70. The company has a 50-day simple moving average of $13.21 and a 200-day simple moving average of $15.03.

MediWound (NASDAQ:MDWD – Get Free Report) last released its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. MediWound had a negative net margin of 234.98% and a negative return on equity of 58.44%. The company had revenue of $3.57 million for the quarter, compared to analyst estimates of $6.73 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in MediWound stock. Marshall Wace LLP acquired a new position in MediWound Ltd. (NASDAQ:MDWD – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,026 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Marshall Wace LLP owned approximately 0.12% of MediWound as of its most recent SEC filing. 46.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.20% of the company’s stock.

MediWound News Summary

These are some of the MDWD news items that stood out recently:

  • Positive Sentiment: CEO and Chairman increased their holdings as a pivotal trial milestone approaches, a potentially supportive insider-confidence signal. Article: MediWound’s CEO and Chairman Increase Their Holdings as a Pivotal Trial Milestone Nears
  • Positive Sentiment: MediWound will host a December 2 KOL event on EscharEx’s Phase III VALUE study and commercial opportunity. The company cited estimated U.S. annual peak sales potential of $1.05 billion; the event may renew investor attention to the program, though it is not a new trial result. Company announcement: MediWound to Host Virtual KOL Event
  • Negative Sentiment: HC Wainwright cut multiple forward EPS estimates, including FY2027 to a loss of $2.07 per share from $2.00, FY2028 to a loss of $1.18 from $0.98, FY2029 profit to $0.51 from $0.75, and FY2030 profit to $1.95 from $2.25. These reductions point to a weaker expected earnings trajectory. The analyst modestly improved FY2026 and Q4 2026 estimates, but those upward revisions were limited. MarketBeat: MediWound analyst estimates

MediWound Company Profile

(Get Free Report)

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.

See Also

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.